Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.

Literature DB >> 22987029

Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.

Joseph S Ross, Rong Wang, Jessica B Long, Cary P Gross, Xiaomei Ma.

Abstract

Entities: Disease Gene Species

Mesh：

Year: 2012 PMID： 22987029 PMCID： PMC3597450 DOI： 10.1001/archinternmed.2012.3726

Source DB: PubMed Journal: Arch Intern Med ISSN： 0003-9926

× No keyword cloud information.

7 in total

1. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.

Authors: Sandip M Prasad; Michael W Drazer; Dezheng Huo; Jim C Hu; Scott E Eggener
Journal: JAMA Date: 2012-04-25 Impact factor: 56.272

2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors:
Journal: Ann Intern Med Date: 2008-08-05 Impact factor: 25.391

3. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.

Authors: Julie Bynum; Yunjie Song; Elliott Fisher
Journal: J Am Geriatr Soc Date: 2010-03-22 Impact factor: 5.562

4. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.

Authors: Emil Scosyrev; Guan Wu; Dragan Golijanin; Edward Messing
Journal: BJU Int Date: 2012-03-27 Impact factor: 5.588

5. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

Authors: Virginia A Moyer
Journal: Ann Intern Med Date: 2012-07-17 Impact factor: 25.391

6. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

Authors: Steven B Zeliadt; Richard M Hoffman; Ruth Etzioni; John L Gore; Larry G Kessler; Daniel W Lin
Journal: J Natl Cancer Inst Date: 2011-02-28 Impact factor: 13.506

7. PSA screening among elderly men with limited life expectancies.

Authors: Louise C Walter; Daniel Bertenthal; Karla Lindquist; Badrinath R Konety
Journal: JAMA Date: 2006-11-15 Impact factor: 56.272

7 in total

12 in total

1. The cost implications of prostate cancer screening in the Medicare population.

Authors: Xiaomei Ma; Rong Wang; Jessica B Long; Joseph S Ross; Pamela R Soulos; James B Yu; Danil V Makarov; Heather T Gold; Cary P Gross
Journal: Cancer Date: 2013-10-04 Impact factor: 6.860

2. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.

Authors: Simon P Kim; R Jeffrey Karnes; Paul L Nguyen; Jeanette Y Ziegenfuss; R Houston Thompson; Leona C Han; Nilay D Shah; Marc C Smaldone; Cary P Gross; Igor Frank; Christopher J Weight; Timothy J Beebe; Jon C Tilburt
Journal: BJU Int Date: 2014-01-17 Impact factor: 5.588

10. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.

Authors: James S Goodwin; Elizabeth Jaramillo; Liu Yang; Yong-Fang Kuo; Alai Tan
Journal: PLoS One Date: 2014-09-10 Impact factor: 3.240

Impact of the 2008 US Preventive Services Task Force recommendation to discontinue prostate cancer screening among male Medicare beneficiaries.

1. 2008 US Preventive Services Task Force recommendations and prostate cancer screening rates.

2. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

3. Variation in prostate-specific antigen screening in men aged 80 and older in fee-for-service Medicare.

4. Prostate-specific antigen testing in older men in the USA: data from the behavioral risk factor surveillance system.

5. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement.

6. Influence of publication of US and European prostate cancer screening trials on PSA testing practices.

7. PSA screening among elderly men with limited life expectancies.

1. The cost implications of prostate cancer screening in the Medicare population.

2. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.

3. Prostate cancer screening practices in a large, integrated health system: 2007-2014.

4. Prostate-specific antigen testing in men aged 40-64 years: impact of publication of clinical trials.

5. Exnovation of Low Value Care: A Decade of Prostate-Specific Antigen Screening Practices.

6. The increase of stage, grading, and metastases in patients undergoing radical prostatectomy during the last decade.

7. Prostate Cancer Screening: A Brief Tool to Incorporate Patient Preferences in a Clinical Encounter.

8. Recent decline in prostate cancer incidence in the United States, by age, stage, and Gleason score.

9. Pediatric screening urinalysis: a difference-in-differences analysis of how a 2007 change in guidelines impacted use.

10. Is anyone listening? Variation in PSA screening among providers for men 75+ before and after United States Preventive Services Task Force recommendations against it: a retrospective cohort study.